Merck Profit Margin 2006-2018 | MRK

Current and historical gross margin, operating margin and net profit margin for Merck (MRK) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Merck net profit margin as of September 30, 2018 is 8.44%.
Merck Annual Profit Margins
Merck Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $204.560B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.628B 16.44
Pfizer (PFE) United States $253.175B 14.27
Novartis AG (NVS) Switzerland $205.567B 17.62
AbbVie (ABBV) United States $134.627B 11.95
Eli Lilly (LLY) United States $123.506B 21.71
Novo Nordisk (NVO) Denmark $117.412B 19.07
Sanofi (SNY) France $104.035B 12.88
GlaxoSmithKline (GSK) United Kingdom $96.892B 13.02
AstraZeneca (AZN) United Kingdom $92.577B 11.49
Bristol-Myers Squibb (BMY) United States $81.806B 13.47